C07K14/473

Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules

A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), Mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.

CHEMOENZYMATIC GLYCOENGINEERING OF ANTIBODIES AND FC FRAGMENTS THEREOF
20210061868 · 2021-03-04 ·

The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.

Method of purification of recombinant osteopontin from micro algae

Provided herein are methods for obtaining purified recombinant osteopontin (rOPN) from cultures of transgenic microalgae, as well as nutritional supplements from such cultures.

Methods for preparing modified von Willebrand factor

The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.

Therapeutic compositions and methods for treatment of muscle wasting diseases

mRNA polymer complexes and drug delivery systems are disclosed herein that include a cationic polymer electrostatically complexed to an mRNA molecule that encodes a desired protein. Also disclosed herein are methods of treating as well as methods of slowing the loss of, increasing, and/or maintaining lean muscle mass in a subject, such as using mRNA polymer complexes and drug delivery systems.

Mechanochemical collagen assembly

Methods and devices are described for using a controlled extensional strain to organize prefibrillar collagen and/or elastin solutions into an organized array of fibrils. The organized array of collagen fibrils produced by the disclosed methods and devices can be used for tissue engineering applications.

AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS

The present invention relates to peptide modifier compounds of Formula (1), or a salt thereof, wherein: a is an integer from 1 to 10, more preferably from 1 to 3; b is an integer from 0 to 7; Z is a terminal group and Y is a bivalent group. Further aspects of the invention relate to intermediates in the preparation of compounds of Formula (1), and the use of compounds of Formula (1) in the synthesis of peptide derivatives.

##STR00001##

Method of managing joint pain

Making an initial evaluation of patient's joint pain when undergoing motions associated stress to the joint such as going up and down stairs, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion is disclosed.

Knee pain evaluation and management via WOMAC and KOOS systems

Knee pain evaluation and management is carried out via intra-articular injections into a patient suffering from knee pain with the injection being comprised of water and a particularly defined peptide. After injection, knee pain is evaluated using a pain subscale such as Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) or Knee injury and Osteoarthritis Outcome Score (KOOS).

Formulation, dosage form and method of reducing knee pain

An injectable aqueous formulation as well as a dosage form is disclosed for use in intra-articular injection of a specific peptide of SEQ ID NO: 1, whereby the joint pain at the injection site is relieved in the absence of detectable changes in joint cartilage formation, with pain particularly relieved under certain stress motions such as walking down stairs.